- Patent Title: Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies
-
Application No.: US15248562Application Date: 2016-08-26
-
Publication No.: US09938346B2Publication Date: 2018-04-10
- Inventor: Jason Baum , Bryan Johnson , Alexey Alexandrovich Lugovskoy , Lihui Xu , Neeraj Kohli , Jonathan Basil Fitzgerald , Sharlene Adams
- Applicant: Merrimack Pharmaceuticals, Inc.
- Applicant Address: US MA Cambridge
- Assignee: Merrimack Pharmaceuticals, Inc.
- Current Assignee: Merrimack Pharmaceuticals, Inc.
- Current Assignee Address: US MA Cambridge
- Agency: Nelson Mullins Riley & Scarborough LLP
- Agent Jane E. Remillard, Esq.; Christopher L. Frank
- Main IPC: C07K16/46
- IPC: C07K16/46 ; C07K16/32 ; C07K16/28 ; C07K16/40 ; C07K16/30 ; A61K39/00

Abstract:
Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.
Public/Granted literature
- US20170051063A1 MONOSPECIFIC AND BISPECIFIC ANTI-IGF-1R AND ANTI-ERBB3 ANTIBODIES Public/Granted day:2017-02-23
Information query